News

The AHEAD program was associated with promising reductions in mean diabetes distress scores among emerging adults with type 1 diabetes.

A combination of in-office and telehealth visits increased visit frequency and maintained glycemic control in older adults with T1D during the COVID-19 pandemic.

The threshold values for the SOF/VEL prophylaxis strategies showed that the 4-week strategy likely won’t be less costly under any reasonable value of the input variables.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.

There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

The citrate-free high-concentration formulation and citrate-containing low-concentration of biosimilar adalimumab-bwwd are now available to patients living in the US.

Unacceptable pain is a significant problem for some patients with rheumatoid arthritis, but what proportion of patients are affected? Test your knowledge with this quiz.

Dr. Juliana Biondo discusses what the future of treatment for hemophilia A looks like based on ongoing trials.

New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.

This endocrine case report from Brady Pregerson, MD, features a man in his 60s with diabetes mellitus presenting with 5 days of nonradiating intermittent lower abdominal pain. Can you determine the correct diagnosis?

Headache, pruritis, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the bulevirtide group compared to the control group.

This cardiology case report from Brady Pregerson, MD, features a man in his late 80s presenting to urgent care with multiple episodes of near syncope in the past 3 days. Check out the ECG and determine the correct diagnosis!

New data indicates that hospital culture must be considered when facilities make significant changes, especially when they concern institutional values.

However, the presence of diabetic retinopathy was observed to have no significant impact on physical health and quality of life compared to subjects without retinopathy.

The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 - 49.2, while the Black population consistently had the highest median state ratios, increasing from 26.7 - 55.4.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

A recap of the top news from the 83rd Scientific Sessions of the American Diabetes Association, including data related to retatrutide, tirzepatide, oral semaglutide, and more!

After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

Our June 2023 cardiology month in review includes 3 FDA approvals, a primary prevention subgroup analysis of CLEAR Outcomes, and a meta-analysis of 13 major trials examining SGLT2 inhibitor use.

While the FDA decision of Roctavian offers patients with hemophilia A more options, the gene therapy eligibility criteria still pose barriers.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

Despite concerns, Dr. Margaret Ragni discusses the significance of the Roctavian's effectiveness for reducing hemophilia A bleeds and improving patient quality of life.

Diabetic retinopathy and microalbuminuria were associated with a significantly higher risk of hemodialysis induction in individuals with T2D.